Bladder Cancer Market to Reach USD 6.04 Billion By 2032

According to analysts at Vantage Market Research, the Global Bladder Cancer Market size is worth 4.2 billion in 2023 and is projected to achieve 6.04 billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 4.1% from 2024 to 2032. The Bladder Cancer Market is experiencing rapid growth driven by 

Industry Overview

Globally, bladder cancer is becoming more common, which is a major factor driving market growth. For instance, according to the Global Cancer Observatory Statistics 2020, Bladder cancer ranks as the 10th most common cancer globally. It is the 6th most prevalent cancer among men and the 17th among women. In 2020, over 573,000 new cases of bladder cancer were reported worldwide. The market is poised for rapid growth, driven by increasing awareness of bladder diseases and available treatments, coupled with expanding healthcare expenditure and the escalating burden of bladder cancer. For instance, in March 2022, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness about warning signs and symptoms.  Over the course of the projected period, initiatives such as these are anticipated to significantly enhance market growth.

North America Dominated Sales with a 44.5% share in 2023.  North America’s dominance can be attributed to several factors such as increasing incidence rate of bladder cancer particularly in the United States. For instance, according to the American Cancer Society’s 2024 statistics, there were approximately 83,190 new cases of bladder cancer in the United States, with 63,070 cases in men and 20,120 cases in women. This high incidence is a result of the aging population and the high prevalence of risk factors like smoking and occupational exposures. Nowadays bladder cancer patients can more easily access modern diagnosis and treatment options because of the reliable healthcare system and sophisticated healthcare infrastructure in North America. Modern medical facilities with cutting edge equipment guarantee that patients receive efficient care on schedule. 

Key Takeaway from the Report

• In 2023, North America accounted for 44.5% of the revenue market share due to the adoption of novel therapies and improved diagnostic techniques, bolstering patient outcomes and driving market growth due to increased awareness and early detection initiatives
• The Asia Pacific region is poised for significant expansion, with a significant CAGR projected throughout the forecast period
• Transitional Cell Bladder Cancer segment dominates the market in 2023 as it’s the most prevalent form of bladder cancer. This has spurred market players increase their efforts in research and innovative treatments 
• In 2023, Chemotherapy emerged as the leading segment in the market, capturing a notable 41.2% market share
• Cystoscopy tests maintained a prominent market share in 2023 for the bladder cancer because cystoscopy is the primary method for direct visualization and biopsy collection, crucial for accurate diagnosis and monitoring of bladder cancer
• In 2023, Hospitals claimed the largest market share at 65.2% in the market due to their specialized facilities for cancer treatment, availability of skilled medical professionals, and comprehensive infrastructure supporting advanced diagnostic and therapeutic interventions

Top Companies

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Bristol-Myers Squibb
• GlaxoSmithKline plc
• Celgene Corporation
• Sanofi S.A.
• Merck & Co.
• Eli Lilly and Company
• AstraZeneca plc

Latest News

UroGen Pharma's UGN-102 Shows Promise in Bladder Cancer Treatment, ATLAS Study Reveals

• In May 2024, UroGen Pharma reports positive findings from analysis of UGN-102 in treating bladder cancer, showing comparable response rates at 12 months for new and recurrent patients. Results suggest potential for UGN-102 as primary treatment option, with Phase 3 ATLAS study demonstrating favorable outcomes compared to standard therapy.

FDA Consents to Evaluate ImmunityBio's N-803 BLA for Non-Muscle-Invasive Bladder Cancer

• In July 2022, the United States Food and Drug Administration (FDA) consented to evaluate ImmunityBio's Biologics License Application (BLA) for N-803, intended for patients with or without Ta or T1 illness who are diagnosed with non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

Nanostics Inc. Launches Clinical Study for ClarityDX Bladder Test in Partnership with University of Alberta and DynaLIFE Medical Labs

• In 2022, Nanostics Inc. embarked on a prospective clinical study aimed at validating ClarityDX Bladder, a minimally invasive diagnostic test for bladder cancer, in collaboration with the University of Alberta’s APCaRI and DynaLIFE Medical Labs. This collaborative effort underscores the commitment to advancing precise and readily accessible diagnostic solutions for bladder cancer.

FDA Approves EPKINLYTM by AbbVie for Advanced Lymphoma Treatment Milestone in 2023

• In 2023, AbbVie achieved a significant milestone as the FDA granted approval for EPKINLYTM (epcoritamab-bysp), marking the first-ever sanction of a T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who have undergone two or more lines of systemic therapies.